Investigating the role of LIN28B in liver cancer spread and blood vessel regulation
Defining pro-metastatic and endothelial-regulatory roles for LIN28B in hepatocellular carcinoma
This study is looking at how a protein called LIN28B affects the spread of liver cancer, aiming to find new ways to treat it by understanding how cancer cells interact with blood vessel cells, and it will also analyze patient samples to discover helpful markers for treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10912067 on NIH RePORTER |
What this research studies
This research focuses on hepatocellular carcinoma (HCC), a severe form of liver cancer that relies on the formation of new blood vessels for growth and spread. The study aims to understand how LIN28B, a protein found in tumors, influences the metastasis of HCC by conducting a series of experiments involving both laboratory cell cultures and animal models. Researchers will analyze how LIN28B affects interactions between HCC cells and endothelial cells, which line blood vessels, to uncover potential new treatment strategies. Additionally, the study will utilize advanced techniques to analyze tumor samples from patients to identify biomarkers that could guide therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma who may benefit from novel treatment approaches.
Not a fit: Patients with other types of cancer or those without hepatocellular carcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target the mechanisms of liver cancer spread and improve patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Franses, Joseph Wang — University of Chicago
- Study coordinator: Franses, Joseph Wang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.